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ABSTRACT
Background: Vitamin D deficiency has been
associated or implicated with the pathophysiology of
the gastrointestinal conditions inflammatory bowel
disease and colorectal cancer, as well as with
depression. No trials or epidemiology studies to date
have investigated a link with irritable bowel syndrome
(IBS). A single case report has suggested a benefit in
IBS of vitamin D supplementation. We hypothesised
that IBS participants with vitamin D insufficiency would
benefit from repletion in terms of their IBS symptoms.
We undertook a pilot trial to provide data to support a
power calculation and to justify a full trial.
Methods: This was a randomised, double blinded,
three-arm parallel design trial of vitamin D, placebo or
a combination of vitamin D and probiotics. Participants
were further stratified according to whether they were
vitamin D replete or insufficient. Vitamin D status was
determined by blood test at baseline and exit; IBS
symptoms were assessed by validated questionnaire;
dietary intakes were assessed by food frequency
questionnaire.
Results: A significant proportion of the IBS population
were vitamin D deficient, such that the replete stratum
could not be adequately recruited. There was a
significant association in the baseline data between
circulating vitamin D level and quality of life (“How
much has IBS affected your life?”). Supplementation
significantly improved vitamin D level versus placebo.
IBS symptoms were not significantly improved in this
pilot, although a power calculation was enabled from
the intervention data.
Conclusions: The IBS population exhibits significant
levels of vitamin D insufficiency and would benefit from
screening and possible supplementation. The impact of
IBS on quality of life may be reduced by vitamin D level.
Future trials should have a sample size of over 97.
Trial registration number: ICTRN 6116003917.
INTRODUCTION
Irritable bowel syndrome (IBS) is a chronic dis-
order which profoundly affects quality of life
with a prevalence of 10–15% in the
industrialised world.1 IBS is a relapsing condi-
tion that has a large social impact and is asso-
ciated with signiﬁcant direct and indirect
Summary box
What is already known about this subject?
▸ Irritable bowel syndrome (IBS) is a chronic func-
tional gastrointestinal (GI) disorder that affects
10–15% of western populations, yet its patho-
genesis and management are poorly
characterised.
▸ Vitamin D supplementation has been associated
with positive outcomes in other lower-GI condi-
tions, including cancer prevention and colitis.
▸ Few studies to date have reported any relation-
ship between vitamin D and IBS, although we
recently reported a case study in this area.
What are the new findings?
▸ The IBS population exhibits low concentrations
of serum 25OHD; these levels respond to
supplementation.
▸ There is a significant positive association
between quality of life and circulating 25OHD
concentrations.
▸ We provide data on which to inform power cal-
culations for a larger clinical trial of vitamin D
supplementation in IBS patients.
How might it impact on clinical practice in
the foreseeable future?
▸ The data provide evidence for widespread
vitamin D insufficiency in people with IBS. There
may be benefit to testing IBS patients’ vitamin D
status and providing supplementation. There is a
positive association between vitamin D status
and quality of life measures, supporting a poten-
tial interaction between vitamin D and mental
health and well-being. Clinicians may consider
trialling vitamin D with patients with IBS as part
of a nutritional management strategy. The
results suggest a larger, adequately powered
trial may be justified.
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Irritable bowel syndrome
healthcare costs.1 It is a heterogeneous disorder that can be
subtyped depending on the bowel habits of patients; IBS
with constipation (IBS-C), IBS with diarrhoea (IBS-D) or
IBS with mixed bowel habits (IBS-M).2
IBS pathogenesis is poorly understood and it is gener-
ally regarded as a multifactorial disorder involving host
and environmental factors, including diet. Most hypoth-
eses involve altered intraluminal milieu, immune activa-
tion, enteric neuromuscular dysfunction and brain–gut
axis dysregulation. It is thought that the intestinal micro-
biota might play an important role as bacterial infection,
antibiotic use and chronic low-grade inﬂammation are
associated with IBS onset.3 Several studies have impli-
cated changes in the colon microbiota may be associated
with IBS symptoms, including perturbation in bile acid
metabolism and electrolyte absorption.4 This theory is
further supported by generally beneﬁcial effects of bac-
teriotherapeutic interventions (vide infra).
Therapy for IBS is primarily targeted at treating the
symptoms experienced, and include loperamide for diar-
rhoea, methylcellulose for constipation and smooth-
muscle relaxants for abdominal pain.2 Nonetheless,
symptom treatment meets with limited success and may
not be effective for long-term management of IBS.
Mounting data suggest that probiotics may be beneﬁcial
in the management of IBS. A recent systematic review of
35 trials investigating probiotic use in IBS showed that 25
of these studies reported a beneﬁcial effect on the primary
outcomes including global symptom severity.5 6 The effect
on secondary outcomes varied between studies with
improvements seen in ﬂatulence and abdominal bloating
following treatment with VSL#3.7 8 Other studies demon-
strated a decrease in abdominal pain after 4 weeks of treat-
ment with Lactobacillus plantarum 299V when compared to
control.9 Our previous work has demonstrated an improve-
ment in global symptom severity in people with IBS follow-
ing 8 weeks of supplementation with LAB4 probiotic.10
We recently reported a case study of an IBS patient
taking high dose (3000 IU daily) vitamin D. The partici-
pant reported remission of IBS symptoms following sup-
plementation, with a recurrence of the symptoms on
supplementation cessation. Additionally, analysis of
social media (blogs/forums) reports from 37 IBS
patients found that 70% described improvements in
their symptoms with supplementation and the majority
of these individuals reported being vitamin D deﬁcient
before supplementation.11 A role for vitamin D supple-
mentation in gastrointestinal health is also supported by
studies showing associations between vitamin D deﬁ-
ciency and inﬂammatory bowel disease (IBD).12
A recent systematic review suggested there may be bene-
ﬁts of vitamin D supplementation in IBD.13
On the basis of our previous case report,11 we
hypothesised that patients with IBS who are vitamin D
insufﬁcient, would report improvement in symptoms fol-
lowing vitamin D supplementation. We further sought to
test whether vitamin D supplementation in combination
with a probiotic preparation would act synergistically.
There are no published randomised controlled trial of
vitamin D supplementation in IBS and therefore no data
on which to base a power calculation. A formal aim of
this trial is to provide data to allow such calculations to
be undertaken, enabling properly scaled clinical trials to
be designed.
MATERIALS AND METHODS
Participants
Ethical approval for this study was granted by The
University of Shefﬁeld Research Ethics Committee (Ref:
SMBRER278). Participants were recruited via poster
advertisements at the University of Shefﬁeld. All partici-
pants had a previous clinical diagnosis of IBS and met
the Rome III criteria at baseline.14 Participants who
reported any antibiotic use in the past 4 weeks prior to
recruitment, recent changes in IBS medication, preg-
nancy, current use of vitamins or probiotic supplements,
history of gastrointestinal surgery, diabetes or current
use of antidepressants or antipsychotics were excluded.
The study population was stratiﬁed by vitamin D status
hypothesising that deﬁcient or insufﬁcient individuals
would respond if deﬁciency were causal in IBS.
Patient measures
Throughout the study participants were assessed using a
number of outcomes. To assess vitamin D status partici-
pants provided a blood sample from which baseline and
exit 25OHD was measured in serum. Participants were
given a food frequency questionnaire (FFQ) from which
dietary intake was derived using FETA opensource soft-
ware.i Baseline IBS symptom questionnaires were com-
pleted.15 The questionnaire assessed abdominal pain
(pain severity and number of days with pain), bloating,
bowel habits (minimum and maximum bowel movement
per day and satisfaction with bowel habit) and quality of
life over each 2-week period.
Study design
This was a 12-week double-blind, placebo-controlled,
stratiﬁed study.
Participants attended the Clinical Research Facility,
Royal Hallamshire Hospital, Shefﬁeld for three visits
(ﬁgure 1). At the ﬁrst visit, baseline 25OHD was mea-
sured in serum, participants completed FFQ and base-
line IBS symptom questionnaires were completed.15
The second visit took place approximately 2 weeks fol-
lowing visit 1. Participants were issued with a 12-week
supply of supplement and were given IBS symptom ques-
tionnaires to be completed biweekly from the date of
visit 2.
At the ﬁnal visit participants provided a second blood
sample from which serum 25OHD was measured. Of the
51 patients issued with supplements 9 failed to return
ihttp://www.srl.cam.ac.uk/epic/epicffq/
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questionnaires for the full period (4 in the placebo
group, 3 vitamin D alone and 2 combined intervention).
Sample size and randomisation
Based on our previous study10 we aimed to recruit
approximately 150 participants. By the end of the study
51 participants were recruited. Recruitment was between
January 2014 and April 2014. Participants were stratiﬁed
by baseline vitamin D statusii (‘Vitamin D deﬁcient’
(25OHD <20 ng/mL) and ‘Vitamin D replete’ (25OHD
>20 ng/mL)) and randomised. Participants were rando-
mised to receive either double placebo (n=17), vitamin
D supplementation and probiotic placebo (n=16) or
probiotic and vitamin D supplementation (n=18).
Participants were allocated in a 1:1:1 ratio to the three
arms of the study according to a computer-generated
random sequence using block randomisation with a
block-size of six. The randomisation was performed by
an independent statistician. Participants were enrolled
and assigned sequentially to placebo or active products.
The allocation sequence was not available to any
member of the research team until databases had been
completed and locked.
Intervention
The probiotic, vitamin D3 and corresponding placebos
were provided by Cultech Ltd, Port Talbot, UK. Vitamin
D3 and the corresponding placebo were provided as
15 mL liquid sublingual sprays. Both contained identical
buffers with placebo lacking the active vitamin D3. Each
spray of vitamin D3 gave a dose containing 3000 IU
vitamin D3.
The probiotic preparation contained two strains of
Lactobacillus acidophilus, CUL60 (NCIMB 30157), CUL21
(NCIMB 30156), Biﬁdobacterium biﬁdum CUL20 (NCIMB
30153) and Biﬁdobacterium animalis subsp. lactis CUL34
(NCIMB 30172) at a total of 2.5×1010 colony forming
units (cfu) per capsule. Volunteers were instructed to
ingest one capsule per day with water and one spray
orally per day for 12 weeks. Compliance was assessed by
counting the number of capsules remaining and weigh-
ing sprays at the end of the intervention—98% compli-
ance was achieved.
Adverse events
There were no adverse events. One participant on the
placebo arm reported feeling unwell after starting the
trial with acute indigestion, heartburn and pain in the
back which subsided after 2 weeks. The participant
halted supplements for 4 weeks and then returned to
the study under the initial time frame.
Biochemical assay
Serum 25OHD was measured using the Cobas e411 auto-
mated immunoassay from Roche Diagnostics (Germany).
The inter assay coefﬁcient of variation (CV) was 4.6%.
Statistical analysis
Number of days with pain were expressed as a percentage
of each 14-day period. All other variables were assessed
using a visual analogue scale and scored of 100.
Individual scores were then combined to give a total
symptom severity score of 500.15 χ2 Test was used to assess
the distribution of participants by vitamin D stratiﬁcation.
Associations between baseline 25OHD stratiﬁcation (deﬁ-
cient: <12.5 ng/mL; insufﬁcient: 12.5–20 ng/mL; replete
20–50 ng/mL; toxic: >50 ng/mL, no recordings were
made at or near the toxic range) and baseline symptom
scores, follow-up 25OHD and change in symptom score
were determined by analysis of variance(ANOVA) with
Bonferroni correction. Pearson’s correlations for vitamin
D intake and baseline serum 25OHD were undertaken.
Change in symptom score over 7 time points were ana-
lysed by repeated measures ANOVA, missing data were
Figure 1 Flow diagram of study protocol. IBS, irritable bowel
syndrome; SSQ, Symptom Severity Questionnaires.
Table 1 Baseline characteristics of participants
Placebo Vitamin D
Vitamin D
+Probiotic
Participants n 18 17 16
Female n 17 15 15
Mean age (±SD) 36 (±15) 34 (±12) 34 (±14)
IBS subtype n
Mixed 10 7 11
Constipation 2 5 2
Diarrhoea 6 5 3
Vitamin D status
Deficient 14 14 12
Replete 4 3 4
Mean serum 25OHD
ng/mL (±SD)
15
(±8.4)
14 (±8.3) 16 (±8.0)
Mean IBS severity
score (±SD)
243 (67) 244 (92) 237 (67)
25OHD, 25-hydroxyvitamin D; IBS, Irritable bowel syndrome.
iihttps://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
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not imputed and were assumed to be missing at random
in the ANOVA model. Comparisons of deﬁcient and
replete symptom scores were assessed by independent t
tests. All tests were two sided with a signiﬁcance value of
<0.05. Analysis was carried out using SPSS V.22 (IBM,
Armonk, New York, USA).
Figure 2 Baseline characteristics of participants (A). Distribution of IBS-subtype across serum 25OHD levels at baseline shows
no significant association of IBS subtype with vitamin D status (B). Mean score for symptom severity at baseline in IBS-C, D and
M participants stratified by vitamin D status at baseline (C). Correlation of baseline 25OHD with vitamin D intake (D).
Table summarising IBS symptom score with vitamin D intake and baseline serum 25OHD. No correlations were detected with in
response to vitamin D intake, however, serum 25OHD showed a negative correlation between quality of life and serum 25OHD.
IBS, irritable bowel syndrome; FFQ, food frequency questionnaire.
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RESULTS
Baseline vitamin D status shows a significant association
with quality of life
Demographics of the population are shown in table 1.
The three arms were similar in terms of number,
gender, age, IBS subtype and serum 25OHD. Overall
IBS symptom severity at baseline (week -2) was similar
between groups (243±67 placebo, 244±92 vitamin D and
237±67 vitamin D with probiotic, p=0.241) and between
IBS subtype (ﬁgure 2A) as was the baseline serum
25OHD (15±8.4, 16±8.0, 14±8.3 ng/mL, p=0.295).
The majority of participants had baseline 25OHD
levels that are considered insufﬁcient/severely deﬁcient16
with an overall sample mean 25OHD of 15.3±7.9 ng/mL
and 81.8% of IBS-C (n=7), 70% of IBS-D (n=9) and
81.6% of IBS-M (n=24) with <20 ng/mL circulating
25OHD levels. This level of deﬁciency was similar to that
seen in a BMI-matched cohort in Shefﬁeld at this time of
year (S. Bowles personal communication, 2014). There
was no association between IBS-subtype and 25OHD
status at baseline (ﬁgure 2B). However, participants with
low 25OHD at baseline reported a greater impact on
quality of life (on the basis of the IBS questionnaire)
than their replete counterparts (p=0.034) (table 2).
There was no difference in other symptom scores
between 25OHD deﬁcient and replete individuals (table
2). Data exploration suggested, a trend for lower affected
quality of life scores in each IBS subtype in vitamin D
replete participants against the non-replete cohort (see
online supplementary, ﬁgure S1c).
We sought to determine whether potential beneﬁts of
replete vitamin D status may be attributed to associations
between systemic effects of 25OHD or the potential
mucosal action of ingested dietary vitamin D. There was
no association between vitamin D intake and symptom
severity, suggesting the effect may be systemically
mediated (ﬁgure 2C, D).
Effect of vitamin D intervention
The distribution of participants by vitamin D status in
each treatment arm was compared at baseline and exit.
An equal distribution was seen at baseline (table 3) and
the distribution was altered by 12 weeks of vitamin D
supplementation. Of participants receiving supplementa-
tion in combination or alone the percentage of partici-
pants who were replete improved from 22.2% and
25.0% to 87.5% and 92.3%, respectively. Participants on
placebo also had higher 25OHD levels with 60% of par-
ticipants replete at exit compared to only 18.5% at base-
line (ﬁgure 3A).
Participants who received vitamin D alone or in com-
bination with probiotic had signiﬁcantly higher 25OHD
at follow-up compared to baseline (15.8±8.0 to 37.2
±9.3 ng/mL and 14.9±8.4 to 37.1±11.7 ng/mL, respect-
ively, p<0.001). These two groups also had higher levels
of 25OHD compared to the placebo group at exit with
mean 25OHD levels of 37 ng/mL while the placebo
group mean was 25.3±8.0 ng/mL (p=0.008 vitamin D,
p=0.005 vitamin D+Probiotic, respectively) (ﬁgure 3A).
While it appeared that there were improved scores in all
reported symptoms from baseline to exit irrespective of
the intervention arm, this was not statistically signiﬁcant
for any symptom tested. Additionally, treatment arm did
not interact with any of the symptom scores at any of the
time point (ﬁgure 3B and online supplementary ﬁgure
S2). The analysis was repeated limited to participants
who were deﬁcient at baseline. A signiﬁcant increase was
seen between baseline and exit 25OHD in all arms
(ﬁgure 3C) with no signiﬁcant relationship of interven-
tion arm on total symptom severity (ﬁgure 3D) or indi-
vidual IBS scores (data not shown).
DISCUSSION
We have presented evidence of high-vitamin D insufﬁ-
ciency in a population with IBS, We have previously
reported anecdotal evidence suggesting a beneﬁt of
vitamin D in management of IBS.11 Baseline data from
our population would support a need for monitoring
vitamin D status and suggests that the impact of vitamin
D deﬁciency is most acute on perceived quality of life.
A correlation indicated a potential relationship
between 25OHD and quality of life scores; however, this
did not reach signiﬁcance. Reported quality of life will
be inﬂuenced by the depression status of participants, a
common comorbidity in IBS.17 Numerous studies have
reported that vitamin D levels are correlated with
depression. In one such study vitamin D deﬁciency in
young healthy individuals predicted clinical depression
across a 4-week period, noting that as vitamin D levels
increased due to seasonal difference in sunlight expos-
ure volunteers showed lower levels of depression.18
A similar pattern was seen in patients suffering post-
Table 2 Baseline symptoms by vitamin D status*
Deficient Replete
Symptom severity 247±70 233±77
Pain severity 44±20 47±24
Pain frequency 37±25 36±24
Distention severity 42±29 40±30
Bowel satisfaction 60±20 58±23
Affected life 62±16 49±21*
Data are means±SD.
*Denotes p<0.05 w.r.t. corresponding deficient symptom,
independent t test.
Table 3 Vitamin D status at baseline and exit
Intervention arm
Baseline (%
sufficient)
Exit (%
sufficient)
Placebo 18.5 60.0
Vitamin D3 22.2 92.3
Vitamin D3
+Probiotic
25.0 87.5
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stroke depression: lower serum vitamin D correlated
with depression.19 The exact mechanism through which
vitamin D improves depression is not fully understood.
However, vitamin D status has been implicated in neuro-
logical development,14 the vitamin D receptor (VDR) is
expressed throughout the nervous system where its acti-
vation is linked to neurotransmitter levels and serotonin
synthesis.20 Additionally binding of 25OHD-VDR
complex results in expression of 1-α-hydroxylase which
converts 25OHD to 1,25-dihydroxyvitamin D.21 This
25OHD metabolite has been shown to upregulate neu-
rotrophins which in turn promote survival and differen-
tiation of nerve cells.22 VDR is also expressed in the gut
and regulates epithelial barrier function and bowel
inﬂammation23 suggesting that a vitamin D deﬁcient
diet may directly impact bowel function and hence IBS
symptomology. Our attempt to distinguish the effects of
circulating and ingested vitamin D did not support
either model, likely due to underpowering.
Supplementation with vitamin D increased serum
25OHD concentrations from baseline with a signiﬁcantly
greater improvement seen compared to participants
receiving placebo. Nonetheless the group receiving
placebo showed an improvement in 25OHD levels. This
may have prevented us from detecting a signiﬁcant dif-
ference in symptom scores between the placebo and
supplemented groups at exit. This general increase in
serum 25OHD across intervention arms was likely due to
seasonal differences in sun exposure. It has been found
in previous studies that the percentage of individuals in
the UK deﬁcient for vitamin D ranges from 30–40%
( January–March) to 2–13% ( July–September).16 Study
participants were recruited in the early months of 2014
( January–April) with most follow-up visits taking place
from May to August, most likely explaining the rise in
25OHD in all groups.
An exploratory analysis of participants by IBS subtype
showed that there was a marked improvement in response
Figure 3 Effect of intervention on participant serum 25OHD concentration and total symptom severity (A). Box plot serum
25OHD concentrations (ng/mL) before and after intervention with placebo, vitamin D3 or vitamin D3+Probiotic (all participants), a
significantly greater increase with vitamin D supplementation alone or with probiotic was seen over placebo group (B). Repeated
measure of total symptom severity against time point (all participants) (C). Box plot serum 25OHD concentrations (ng/mL) before
and after intervention with placebo, vitamin D3 or vitamin D3+Probiotic. (deplete participants only), a significant increase in
serum 25OHD was seen in all groups with a greater response associated with vitamin D supplementation alone or with probiotic
when compared to placebo group (D). Repeated measure of total symptom severity against time point (deplete participants only).
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to vitamin D supplementation across nearly all IBS symp-
toms in participants with IBS-C (see online supplementary
ﬁgure S3). Interestingly the proportion of these partici-
pants that were considered severely deﬁcient was low in
comparison to the other IBS subtypes (ﬁgure 2B). A clear
limitation is the very small numbers in groups when the
data is split but the observation suggests a future study into
vitamin D supplementation in this subgroup may be
justiﬁed.
Throughout this study we failed to observe a signiﬁcant
interaction with intervention with either vitamin D alone
or in combination with probiotic. This is likely explained
by a number of limitations in the study. First, we observed
an effect of the placebo on symptom scores: IBS symp-
toms have a highly variable course (compare week-2 and
0 in ﬁgures 3B, D for example). It is recommended that
active intervention in IBS last a minimum of 4 weeks and
potentially up to 6 months for long-term analysis.24
Furthermore, as a pilot study the current trial is inher-
ently underpowered. In order to detect a statistically sig-
niﬁcant response in total symptom severity scores we
would need larger sample sizes. With the data generated
in this study it was calculated that a sample size of 74 per
arm would be needed. This was calculated based on
change in total symptom severity at exit with a placebo
mean of −16, a mean of −54 for vitamin D intervention,
a combined SD of 82 and assuming a desired power of
80% with an α error of 0.05.
It is possible that seasonal variations in vitamin D
levels may impact IBS in the current study. Our data
show a general improvement in symptom score and
improved 25OHD over the duration of this study is
tempting to speculate that increased sunlight exposure
increases vitamin D levels which in turn improved IBS
symptoms. Such effects have been previously shown for
IBS and IBD symptoms.25 26 However, there was a signiﬁ-
cantly greater effect of vitamin D intervention than
placebo on circulating vitamin D. Taken together, these
data suggestion that seasonal variation should also be
taken into account in the design of trials to assess the
potential application of vitamin D in IBS.
In summary we have shown that IBS sufferers deﬁcient
in vitamin D experience poorer quality of lives than
their replete counterparts. Our data demonstrate the
need for additional studies of more than 8 weeks in dur-
ation with recruitment of a larger cohort of IBS patients.
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